No Clear Winner in SGLT2 Showdown for Cardiovascular Disease

(MedPage Today) -- Individual SGLT2 inhibitors showed roughly comparable cardiovascular effectiveness and safety in an observational study of real-world claims data.
Compared with people who had type 2 diabetes treated with empagliflozin (Jardiance...